Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

A new study finds that even light-to-moderate alcohol consumption may be linked to increased amyloid beta deposition, a key ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

A recent study published in Brain Communications has shed light on how traumatic brain injuries, such as those experienced in combat or accidents, might influence the development of brain changes ...

A comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP) in Alzheimer’s disease (AD). CD2AP influences amyloid-beta processing, ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

The researchers have been testing amyloid-removing therapies ... with sticky plaques made from beta amyloid proteins and toxic tangles made of a protein called tau. They theorized that removing ...

The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...